Elsevier

The Lancet Oncology

Volume 19, Issue 10, October 2018, Pages 1278-1280
The Lancet Oncology

Comment
Does GDPR harm or benefit research participants? An EORTC point of view

https://doi.org/10.1016/S1470-2045(18)30620-XGet rights and content

First page preview

First page preview
Click to open first page preview

References (6)

There are more references available in the full text version of this article.

Cited by (13)

  • Current models, challenges and best practices for work conducted between European academic cooperative groups and industry

    2020, ESMO Open
    Citation Excerpt :

    A best practice proposal would be to segment, in advance, those countries that interpret clinical trial legislation to not allow sharing of data with industry for non-commercial trials to ensure that the considerations written above have been adequately described to them. Finally, there is a lack of guidance concerning the implementation of the General Data Protection Regulation (GDPR), which creates difficulties for international collaborations in clinical research.5 6 GDPR must be viewed in light of the upcoming EU CTR, in vitro diagnostic regulations and medical devices regulations.

  • Clinical trial app regulations

    2020, Innovation in Clinical Trial Methodologies: Lessons Learned during the Corona Pandemic
  • GDPR—not just an EU regulation?

    2018, The Lancet Oncology
View all citing articles on Scopus
View full text